IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin
- PMID: 15126102
- DOI: 10.1016/j.yexmp.2003.12.010
IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin
Abstract
Bleomycin yields pulmonary injury characterized by inflammation that proceeds to fibrosis. The production of IL-10 by pulmonary macrophages is increased in the inflammation that accompanies bleomycin lung injury. In the present study, IL-10 deficient and wildtype mice received 0.075 units of bleomycin intratracheally at day 0 and were sacrificed at day 7 or day 14. At day 7, pulmonary inflammation was increased in IL-10-deficient mice as reflected by increased representation of CD3+ and CD4+ lymphocytes and GR-1+ pulmonary granulocytes in the bronchoalveolar lavage (BAL) fluid. Pulmonary interstitial CD80+ and CD86+ mononuclear cells were increased in situ. At day 14, mononuclear cell inflammation was comparable between groups but pulmonary eosinophils were increased in the wildtype. There was no difference in the degree of pulmonary fibrosis, as judged by histology or lung hydroxyproline content. Lung chemokine expression of MIP-1alpha/beta, MIP-2, and eotaxin was increased at days 7 and 14 with a trend towards increased MCP-1 expression at day 14. The findings suggest an immunomodulatory role for IL-10 in the inflammatory response but not in the pulmonary fibrosis yielded by bleomycin.
Similar articles
-
IL-12p40(-/-) mice treated with intratracheal bleomycin exhibit decreased pulmonary inflammation and increased fibrosis.Exp Mol Pathol. 2002 Feb;72(1):1-9. doi: 10.1006/exmp.2001.2409. Exp Mol Pathol. 2002. PMID: 11784117
-
TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury.J Leukoc Biol. 1998 Oct;64(4):528-36. J Leukoc Biol. 1998. PMID: 9766634
-
C-C chemokine receptor 2 (CCR2) deficiency improves bleomycin-induced pulmonary fibrosis by attenuation of both macrophage infiltration and production of macrophage-derived matrix metalloproteinases.J Pathol. 2004 Dec;204(5):594-604. doi: 10.1002/path.1667. J Pathol. 2004. PMID: 15538737
-
Possible mechanisms of bleomycin-induced fibrosis.Clin Chest Med. 1990 Mar;11(1):21-30. Clin Chest Med. 1990. PMID: 1691068 Review.
-
Bleomycin and pulmonary toxicity.Neth J Med. 1985;28(11):516-23. Neth J Med. 1985. PMID: 2417127 Review. No abstract available.
Cited by
-
The counter regulatory response induced by CpG oligonucleotides prevents bleomycin induced pneumopathy.Respir Res. 2012 Jun 18;13(1):47. doi: 10.1186/1465-9921-13-47. Respir Res. 2012. PMID: 22708497 Free PMC article.
-
Macrophage heterogeneity in respiratory diseases.Mediators Inflamm. 2013;2013:769214. doi: 10.1155/2013/769214. Epub 2013 Feb 27. Mediators Inflamm. 2013. PMID: 23533311 Free PMC article. Review.
-
Rapid reactivation of extralymphoid CD4 T cells during secondary infection.PLoS One. 2011;6(5):e20493. doi: 10.1371/journal.pone.0020493. Epub 2011 May 27. PLoS One. 2011. PMID: 21647373 Free PMC article.
-
Expression and Presence of OPG and RANKL mRNA and Protein in Human Periodontal Ligament with Orthodontic Force.Gene Regul Syst Bio. 2016 Jan 25;10:15-20. doi: 10.4137/GRSB.S35368. eCollection 2016. Gene Regul Syst Bio. 2016. PMID: 26823650 Free PMC article.
-
Salt-inducible kinase 2 regulates fibrosis during bleomycin-induced lung injury.J Biol Chem. 2022 Dec;298(12):102644. doi: 10.1016/j.jbc.2022.102644. Epub 2022 Oct 26. J Biol Chem. 2022. PMID: 36309093 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous